Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

Psyence BioMed announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives. The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds, including ibogaine. The purpose of the Company’s upcoming U.S. engagement initiative is to educate and inform stakeholders on the complexity, regulatory considerations, and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under Good Manufacturing Practice standards suitable for regulated clinical research. “We believe global interest in ibogaine research continues to accelerate, particularly as policymakers, researchers, and healthcare institutions explore innovative approaches to serious mental health conditions,” said Jody Aufrichtig, CEO of Psyence BioMed. “Our objective during this visit is to contribute constructively to those conversations by sharing our expertise and helping stakeholders better understand the highly specialized process required to produce compliant pharmaceutical-grade ibogaine suitable for regulated research environments.”